m6A Target Gene Information

General Information of the m6A Target Gene (ID: M6ATAR00389)
Target Name Translocation protein SEC62 (SEC62)
Synonyms
Translocation protein 1; TP-1; hTP-1; TLOC1
    Click to Show/Hide
Gene Name SEC62
Chromosomal Location 3q26.2
Family SEC62 family
Function
Mediates post-translational transport of precursor polypeptides across endoplasmic reticulum (ER). Proposed to act as a targeting receptor for small presecretory proteins containing short and apolar signal peptides. Targets and properly positions newly synthesized presecretory proteins into the SEC61 channel-forming translocon complex, triggering channel opening for polypeptide translocation to the ER lumen.
    Click to Show/Hide
Gene ID 7095
Uniprot ID
SEC62_HUMAN
HGNC ID
HGNC:11846
Ensembl Gene ID
ENSG00000008952
KEGG ID
hsa:7095
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
SEC62 can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Browse Drug
Methyltransferase-like 3 (METTL3) [WRITER]
 Regulator Info 
Representative RNA-seq result indicating the expression of this target gene regulated by METTL3
Cell Line CT26 cell line Mus musculus
Treatment: METTL3 knockout CT26 cells
Control: CT26 cells
 GSE142589
Regulation
logFC: -8.61E-01
p-value: 1.21E-03
More Results Click to View More RNA-seq Results
Representative RIP-seq result supporting the interaction between SEC62 and the regulator
Cell Line MDA-MB-231 Homo sapiens
Regulation logFC: 1.99E+00 GSE60213
In total 3 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [1]
Response Summary miR-4429 prevented gastric cancer progression through targeting METTL3 to inhibit m6A-caused stabilization of Translocation protein SEC62 (SEC62), indicating miR-4429 as a promising target for treatment improvement for Gastric cancer. METTL3 interacted with SEC62 to induce the m6A on SEC62 mRNA, therefore facilitated the stabilizing effect of IGF2BP1 on SEC62 mRNA.
Target Regulation Up regulation
Responsed Disease Gastric cancer ICD-11: 2B72
 Disease Info 
Pathway Response Protein processing in endoplasmic reticulum hsa04141
Cell Process RNA stability
Cell apoptosis
In-vitro Model GES-1 Normal Homo sapiens CVCL_EQ22
HGC-27 Gastric carcinoma Homo sapiens CVCL_1279
MGC-803 Gastric mucinous adenocarcinoma Homo sapiens CVCL_5334
MKN45 Gastric adenocarcinoma Homo sapiens CVCL_0434
MKN45 Gastric adenocarcinoma Homo sapiens CVCL_0434
Experiment 2 Reporting the m6A Methylation Regulator of This Target Gene [2]
Response Summary Translocation protein SEC62 (SEC62) upregulated by the METTL3-mediated m6A modification promotes the stemness and chemoresistance of colorectal cancer by binding to beta-catenin and enhancing Wnt signalling. Depletion of Sec62 sensitized the CRC cells to 5-Fu or oxaliplatin treatment.
Target Regulation Up regulation
Responsed Disease Colorectal cancer ICD-11: 2B91
 Disease Info 
Responsed Drug Fluorouracil Approved
 Drug Info 
Pathway Response Wnt signaling pathway hsa04310
Cell Process Protein degradation
In-vitro Model DLD-1 Colon adenocarcinoma Homo sapiens CVCL_0248
HT29 Colon cancer Mus musculus CVCL_A8EZ
In-vivo Model DLD-1 cells were subcutaneously implanted into 4-6 weeks old female nude mice. When tumors reached a size of about 50 mm3, the nude mice were randomly divided into 6 groups.
Experiment 3 Reporting the m6A Methylation Regulator of This Target Gene [2]
Response Summary Translocation protein SEC62 (SEC62) upregulated by the METTL3-mediated m6A modification promotes the stemness and chemoresistance of colorectal cancer by binding to beta-catenin and enhancing Wnt signalling. Depletion of Sec62 sensitized the CRC cells to 5-Fu or oxaliplatin treatment.
Target Regulation Up regulation
Responsed Disease Colorectal cancer ICD-11: 2B91
 Disease Info 
Responsed Drug Oxaliplatin Approved
 Drug Info 
Pathway Response Wnt signaling pathway hsa04310
Cell Process Protein degradation
In-vitro Model DLD-1 Colon adenocarcinoma Homo sapiens CVCL_0248
HT29 Colon cancer Mus musculus CVCL_A8EZ
In-vivo Model DLD-1 cells were subcutaneously implanted into 4-6 weeks old female nude mice. When tumors reached a size of about 50 mm3, the nude mice were randomly divided into 6 groups.
Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) [READER]
 Regulator Info 
Representative RNA-seq result indicating the expression of this target gene regulated by IGF2BP1
Cell Line HepG2 cell line Homo sapiens
Treatment: siIGF2BP1 HepG2 cells
Control: siControl HepG2 cells
 GSE161086
Regulation
logFC: -8.16E-01
p-value: 3.16E-03
More Results Click to View More RNA-seq Results
In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [1]
Response Summary miR-4429 prevented gastric cancer progression through targeting METTL3 to inhibit m6A-caused stabilization of Translocation protein SEC62 (SEC62), indicating miR-4429 as a promising target for treatment improvement for Gastric cancer. METTL3 interacted with SEC62 to induce the m6A on SEC62 mRNA, therefore facilitated the stabilizing effect of IGF2BP1 on SEC62 mRNA.
Target Regulation Up regulation
Responsed Disease Gastric cancer ICD-11: 2B72
 Disease Info 
Pathway Response Protein processing in endoplasmic reticulum hsa04141
Cell Process RNA stability
Cell apoptosis
In-vitro Model GES-1 Normal Homo sapiens CVCL_EQ22
HGC-27 Gastric carcinoma Homo sapiens CVCL_1279
MGC-803 Gastric mucinous adenocarcinoma Homo sapiens CVCL_5334
MKN45 Gastric adenocarcinoma Homo sapiens CVCL_0434
MKN45 Gastric adenocarcinoma Homo sapiens CVCL_0434
Gastric cancer [ICD-11: 2B72]
 Disease Info 
In total 2 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response [1]
Response Summary miR-4429 prevented gastric cancer progression through targeting METTL3 to inhibit m6A-caused stabilization of Translocation protein SEC62 (SEC62), indicating miR-4429 as a promising target for treatment improvement for Gastric cancer. METTL3 interacted with SEC62 to induce the m6A on SEC62 mRNA, therefore facilitated the stabilizing effect of IGF2BP1 on SEC62 mRNA.
Responsed Disease Gastric cancer [ICD-11: 2B72]
Target Regulator Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) READER
 Regulator Info 
Target Regulation Up regulation
Pathway Response Protein processing in endoplasmic reticulum hsa04141
Cell Process RNA stability
Cell apoptosis
In-vitro Model GES-1 Normal Homo sapiens CVCL_EQ22
HGC-27 Gastric carcinoma Homo sapiens CVCL_1279
MGC-803 Gastric mucinous adenocarcinoma Homo sapiens CVCL_5334
MKN45 Gastric adenocarcinoma Homo sapiens CVCL_0434
MKN45 Gastric adenocarcinoma Homo sapiens CVCL_0434
Experiment 2 Reporting the m6A-centered Disease Response [1]
Response Summary miR-4429 prevented gastric cancer progression through targeting METTL3 to inhibit m6A-caused stabilization of Translocation protein SEC62 (SEC62), indicating miR-4429 as a promising target for treatment improvement for Gastric cancer. METTL3 interacted with SEC62 to induce the m6A on SEC62 mRNA, therefore facilitated the stabilizing effect of IGF2BP1 on SEC62 mRNA.
Responsed Disease Gastric cancer [ICD-11: 2B72]
Target Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
Target Regulation Up regulation
Pathway Response Protein processing in endoplasmic reticulum hsa04141
Cell Process RNA stability
Cell apoptosis
In-vitro Model GES-1 Normal Homo sapiens CVCL_EQ22
HGC-27 Gastric carcinoma Homo sapiens CVCL_1279
MGC-803 Gastric mucinous adenocarcinoma Homo sapiens CVCL_5334
MKN45 Gastric adenocarcinoma Homo sapiens CVCL_0434
MKN45 Gastric adenocarcinoma Homo sapiens CVCL_0434
Colorectal cancer [ICD-11: 2B91]
 Disease Info 
In total 2 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response [2]
Response Summary Translocation protein SEC62 (SEC62) upregulated by the METTL3-mediated m6A modification promotes the stemness and chemoresistance of colorectal cancer by binding to beta-catenin and enhancing Wnt signalling. Depletion of Sec62 sensitized the CRC cells to 5-Fu or oxaliplatin treatment.
Responsed Disease Colorectal cancer [ICD-11: 2B91]
Target Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
Target Regulation Up regulation
Responsed Drug Fluorouracil Approved
 Drug Info 
Pathway Response Wnt signaling pathway hsa04310
Cell Process Protein degradation
In-vitro Model DLD-1 Colon adenocarcinoma Homo sapiens CVCL_0248
HT29 Colon cancer Mus musculus CVCL_A8EZ
In-vivo Model DLD-1 cells were subcutaneously implanted into 4-6 weeks old female nude mice. When tumors reached a size of about 50 mm3, the nude mice were randomly divided into 6 groups.
Experiment 2 Reporting the m6A-centered Disease Response [2]
Response Summary Translocation protein SEC62 (SEC62) upregulated by the METTL3-mediated m6A modification promotes the stemness and chemoresistance of colorectal cancer by binding to beta-catenin and enhancing Wnt signalling. Depletion of Sec62 sensitized the CRC cells to 5-Fu or oxaliplatin treatment.
Responsed Disease Colorectal cancer [ICD-11: 2B91]
Target Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
Target Regulation Up regulation
Responsed Drug Oxaliplatin Approved
 Drug Info 
Pathway Response Wnt signaling pathway hsa04310
Cell Process Protein degradation
In-vitro Model DLD-1 Colon adenocarcinoma Homo sapiens CVCL_0248
HT29 Colon cancer Mus musculus CVCL_A8EZ
In-vivo Model DLD-1 cells were subcutaneously implanted into 4-6 weeks old female nude mice. When tumors reached a size of about 50 mm3, the nude mice were randomly divided into 6 groups.
Fluorouracil [Approved]
 Drug Info 
In total 1 item(s) under this drug
Experiment 1 Reporting the m6A-centered Drug Response [2]
Response Summary Translocation protein SEC62 (SEC62) upregulated by the METTL3-mediated m6A modification promotes the stemness and chemoresistance of colorectal cancer by binding to beta-catenin and enhancing Wnt signalling. Depletion of Sec62 sensitized the CRC cells to 5-Fu or oxaliplatin treatment.
Target Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
Target Regulation Up regulation
Responsed Disease Colorectal cancer ICD-11: 2B91
 Disease Info 
Pathway Response Wnt signaling pathway hsa04310
Cell Process Protein degradation
In-vitro Model DLD-1 Colon adenocarcinoma Homo sapiens CVCL_0248
HT29 Colon cancer Mus musculus CVCL_A8EZ
In-vivo Model DLD-1 cells were subcutaneously implanted into 4-6 weeks old female nude mice. When tumors reached a size of about 50 mm3, the nude mice were randomly divided into 6 groups.
Oxaliplatin [Approved]
 Drug Info 
In total 1 item(s) under this drug
Experiment 1 Reporting the m6A-centered Drug Response [2]
Response Summary Translocation protein SEC62 (SEC62) upregulated by the METTL3-mediated m6A modification promotes the stemness and chemoresistance of colorectal cancer by binding to beta-catenin and enhancing Wnt signalling. Depletion of Sec62 sensitized the CRC cells to 5-Fu or oxaliplatin treatment.
Target Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
Target Regulation Up regulation
Responsed Disease Colorectal cancer ICD-11: 2B91
 Disease Info 
Pathway Response Wnt signaling pathway hsa04310
Cell Process Protein degradation
In-vitro Model DLD-1 Colon adenocarcinoma Homo sapiens CVCL_0248
HT29 Colon cancer Mus musculus CVCL_A8EZ
In-vivo Model DLD-1 cells were subcutaneously implanted into 4-6 weeks old female nude mice. When tumors reached a size of about 50 mm3, the nude mice were randomly divided into 6 groups.
References
Ref 1 MiR-4429 prevented gastric cancer progression through targeting METTL3 to inhibit m(6)A-caused stabilization of SEC62. Biochem Biophys Res Commun. 2019 Oct 1;517(4):581-587. doi: 10.1016/j.bbrc.2019.07.058. Epub 2019 Aug 5.
Ref 2 Sec62 promotes stemness and chemoresistance of human colorectal cancer through activating Wnt/Beta-catenin pathway. J Exp Clin Cancer Res. 2021 Apr 15;40(1):132. doi: 10.1186/s13046-021-01934-6.